Pfizer Hits LAVA's PF-08046052 Development Milestone in Phase 1 Clinical Trial

LAVA Therapeutics N.V. (NASDAQ: LVTX), a clinical-stage immuno-oncology company concentrating on its proprietary Gammabody® platform for bispecific gamma delta T cell engagers, has announced a notable development. Pfizer has achieved a clinical milestone for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223), triggering a $7 million payment to LAVA. This follows LAVA's granting of an exclusive global license for PF-08046052 to Seagen (acquired by Pfizer) in September 2022.

Stephen Hurly, President and CEO of LAVA, expressed satisfaction with Pfizer's clinical development initiation of PF-08046052, noting its promising potential in oncology and its importance in advancing LAVA’s Gammabody® platform. He anticipates continued progress in the Phase 1 study and future data updates.

Charles Morris, M.D., Chief Medical Officer of LAVA, remarked that this milestone marks the third use of LAVA’s Gammabody® platform entering clinical trials. The ongoing study will expand the understanding of the safety, pharmacology, and possible anti-tumor effects of this novel class of molecules. He highlighted the progress of both PF-08046052 and LAVA-1207, the latter currently in a Phase 1/2a study for prostate cancer.

PF-08046052 is designed to selectively activate Vγ9Vδ2 T cells to target and kill EGFR-positive tumor cells. It is under evaluation in a current Phase 1 study by Pfizer, under a broader licensing agreement. The agreement included a $50 million upfront payment and allows for potential milestone payments of up to $650 million, plus sales royalties.

LAVA Therapeutics focuses on using its Gammabody® platform to develop treatments for both solid tumors and blood cancers. The company’s leading program, LAVA-1207, is under investigation in a dose-escalation study for metastatic castration-resistant prostate cancer in the US and Europe, exploring both monotherapy and combination treatments, including the potential addition of KEYTRUDA® via partnership with Merck & Co., Inc.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!